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Background: Metabolic syndrome is a cluster of metabolic risk factors including dyslipidemia, impaired glucose
tolerance, hypertension and central obesity. BDNF (Brain-derived neurotrophic factor) and leptin have been implied
in the energy homeostasis. The purposes of this study were to examine concentrations of leptin, BDNF and
biochemical parameters in metabolic-syndrome subjects and healthy controls, and also to search for associations of
leptin gene (LEP) G2548A, leptin receptor gene (LEPR) Gln223Arg, and BDNF gene (BDNF) Val66Met polymorphisms
with leptin levels, BDNF levels and metabolic syndrome among Thais.
Methods: The case-controlled design was performed using 322 Thai volunteers (160 metabolic-syndrome subjects;
162 controls) during the health screening program. Metabolic syndrome was assessed by using the modified
National Cholesterol Education Program, Adult Treatment Panel III criteria. The levels of leptin, BDNF, insulin, glucose
and lipids were measured in samples. Genotyping of LEP G2548A, LEPR Gln223Arg and BDNF Val66Met was carried
out using polymerase chain reaction-restriction fragment length polymorphism technique.
Results: Serum leptin levels were significantly higher in the metabolic-syndrome group than the control group
(p < 0.01), but the BDNF difference between them was not significant. Significant associations of LEPR Gln223Arg
polymorphism were found with leptin and glucose levels (p < 0.05), after adjusting for potential covariates. This
LEPR polymorphism in the metabolic-syndrome group was also significantly more frequent than in the control
group (p < 0.05). However, other gene polymorphisms, LEP G2548A and BDNF Val66Met, showed no significant
relationship with leptin levels, BDNF levels or metabolic syndrome.
Conclusion: These findings suggest leptin levels are linked with metabolic syndrome. LEPR Gln223Arg
polymorphism impacted leptin concentrations, and this gene polymorphism may influence susceptibility to
metabolic syndrome among Thais.
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Metabolic syndrome (MS), which involves abdominal
obesity, dyslipidemia, hypertension, and glucose toler-
ance represents one of the world’s most challenging
health problems, and is an important risk factor for type
2 diabetes and cardiovascular diseases [1]. Leptin, an* Correspondence: kanjana.su@rsu.ac.th
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reduce food intake, increase energy expenditure, and
modulate immune and inflammatory responses by bind-
ing and activating the leptin receptor [2]. Serum leptin is
proportional to body adiposity [3]. There are several
studies indicating links of leptin gene (LEP) and leptin
receptor gene (LEPR) variations with obesity [4], insulin
resistance [5], and type 2 diabetes [6]. The gene polymor-
phisms of LEP G2548A (rs7799039: guanine > adenine)
and LEPR Gln223Arg (rs1137101: glutamine > arginine)tral Ltd. This is an open access article distributed under the terms of the
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ated with leptin production and secretion [7], and LEPR
Gln223Arg has been associated with impaired signaling
capacity of the leptin receptor [8]. However, evidence for an
association of LEP G2548A and LEPR Gln223Arg with lep-
tin concentrations and MS is inconsistent [9-11]. Moreover,
the relationship of LEP G2548A and LEPR Gln223Arg
gene polymorphisms with MS among Thais has not been
investigated to date.
Brain-derived neurotrophic factor (BDNF) is a mem-
ber of the neurotrophic factor family and is one of the
molecules that mediate the function in the control of en-
ergy balance. The associations of BDNF and leptin with
functions involved in energy homeostasis have been
studied [12]. Previous studies have shown links between
BDNF concentrations and obesity and diabetes [13,14].
The most common BDNF gene (BDNF) polymorphism,
Val66Met (rs6265: valine > methionine), affects intracel-
lular trafficking of pro-BDNF, and also decreases secre-
tion and production of the mature BDNF with the Met
allele [15]. However, previous studies have shown incon-
sistent results in relation to BDNF concentrations in MS
subjects [16,17], and information on BDNF Val66Met
gene polymorphism and MS is scarce. Therefore, the
aims of this study were to examine concentrations of
leptin, BDNF and biochemical parameters in MS sub-
jects and healthy controls, and to search for links of LEP
G2548A, LEPR Gln223Arg and BDNF Val66Met gene
polymorphisms with leptin levels, BDNF levels and MS
among Thais.Methods
Following approval by the Ethics Committee of Rangsit
University (RSEC No.016/53), Thailand and in accord-
ance with the Declaration of Helsinki, this case-control
study enrolled 322 Thai volunteers aged between 24 to
64 years and living in urban and suburban residential
areas of Bangkok, Thailand. Among them, 162 healthy
controls (86 male, 76 female) and 160 MS subjects (73
male, 87 female) were chosen during the health screen-
ing program among check-up subjects in March 2011-
February 2012 and the statistical power in our sample
size calculation was 80% at alpha =0.05. A physical
examination and medical history check on all subjects
was performed. Subjects with a history of liver, kidney
and cardiovascular diseases were excluded from the
study. Metabolic syndrome was defined using the modi-
fied National Cholesterol Education Program/Adult
Treatment Panel III (NCEP/ATP III) criteria [18]. The
new cut-off for waist circumference in the Asia-Pacific
Region, instead of the original cut-off in the ATP III cri-
teria, was used. Adoption of the new cut-off point for
fasting plasma glucose criterion has already been reported(> 100 mg/dl). The modified NCEP/ATP III definition re-
quired at least three of the following: raised triglyceride
(TG) levels: > 150 mg/dl, reduced high-density lipoprotein
cholesterol (HDL-C): < 40 mg/dl in men, and < 50 mg/dl
in women, raised fasting plasma glucose: > 100 mg/dl,
raised waist circumference (WC): > 90 cm in Asian men
and > 80 cm in Asian women or raised blood pressure: sys-
tolic blood pressure > 130 mmHg or diastolic blood pres-
sure > 85.
Anthropometric measurements
The body weight of each subject was measured using a
carefully calibrated beam balance (Detecto®, Cardinal
Detecto Scale Manufacturing, MO). Height was mea-
sured using a vertical measuring rod. Body mass index
(BMI) was conventionally expressed as weight (kg)/
height (m2). Waist and hip circumferences were mea-
sured. Waist and hip circumferences were calculated for
waist and hip circumference ratio. Furthermore, this
study had also determined triceps skin-fold thickness
(TSF) and arm circumference (AC) because TSF was
suggested as the simple predictor of body density and
hence percentage total body fat [19] and AC measure-
ment could reflect adult nutritional status as defined by
BMI [20]. The upper arm length midpoint mark was
used to measure TSF and AC. The TSF was measured by
using the Holtain Skinfold Caliper. Blood pressure (BP)
was measured by a nurse after 5 to 10 minutes’ rest in
the sitting position.
Laboratory measurements
10 ml of venous blood was taken from subjects in the
morning after overnight fast. Glucose, TG, HDL-C levels
were measured using enzymatic methods by DADE Dimen-
sion AR®. Leptin and insulin levels were measured using
a radioimmunoassay kit from Linco Research (St Louis,
USA). Serum BDNF levels were determined using an
ELISA protocol, according to the manufacturer’s instruc-
tions (DBD00; R & D Systems, Europe).
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) technique
DNA was extracted from EDTA-treated whole blood by
FlexiGene DNA kit (Qiagen, Hilden, Germany). Genotyp-
ing of BDNF Val66Met, LEP G2548A and LEPR Gln223Arg
was carried out using PCR-RFLP assay. DNA fragments
were amplified by PCR (PE Applied Biosystems). For ana-
lysis of the BDNF Val66Met polymorphism, the following
primers were used:
Forward primer – 5′-ATCCGAGGACAAGGTGGC-3′
Reverse primer – 5′-CCTCATGGACATGTTTGCAG-3′
A 50 μl PCR reaction was performed according to the
protocol described by Matsushita et al. [21]. For analysis
Figure 2 Restriction fragments length polymorphism (RFLP)
distribution pattern of LEP G2548A polymorphism. Lane 1 =
ladder (50 bp), Lane 2 = G/A (242,181, and 61 bp), Lane 3-4 = G/G
(181 and 61 bp), Lane 5 = A/A (242 bp).
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were used:
Forward primer – 5′-TTTCTGTAATTTTCCCGTG
AG-3′
Reverse primer – 5′-AAAGCAAAGACAGGCATA
AAAA-3′
A 50 μl PCR reaction was conducted, according to the
protocol described by Boumaiza et al. [10]. For analysis
of the LEPR Gln223Arg polymorphism, the following
primers were used:
Forward primer – 5′-ACCCTTTAAGCTGGGTGTCC
CAAATAG-3′
Reverse primer – 5′-AGCTAGCAAATATTTTTGTA
AGCAATT-3′
A 50 μl PCR reaction was conducted, according to the
protocol described by Duarte et al. [4]. PCR products
(304 bp for BDNF, 242 bp for LEP and 421 bp for LEPR)
were detected on 2% agarose gel containing ethidium
bromide. Aliquots of the PCR products were digested
with 8 U PmlI, HhaI and MspI restriction enzymes for
the BDNF Val66Met, the LEP G2548A, and the LEPR
Gln223Arg polymorphisms, respectively. Alleles were
visualized as fragments by electrophoresis through an
ethidium bromide-stained 2.5% agarose gel. Distribution
patterns of the BDNF Val66Met, the LEP G2548A, and
the LEPR Gln223Arg polymorphisms were shown in
Figures 1, 2, 3.
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows version 11.5 (SPSS, Chicago, IL). Median, rangeFigure 1 Restriction fragments length polymorphism (RFLP)
distribution pattern of BDNF Val66Met polymorphism. Lane 1 =
ladder (50 bp), Lane 2 = Val/Val (124 and 180 bp), Lane 3 = Val/Met
(304, 180 and 124 bp), Lane 4 = Met/Met (304 bp).and 95% confidence intervals (CI) were calculated. The
difference between the two groups was compared by
Mann-Whitney U/Wilcoxon Rank Sum W test. The dif-
ferences in genotypic and allelic frequencies of the two
groups were assessed by Chi-square test. The Minitab
statistical computer program was used to calculate the
odds ratio (OR). Spearman rank was used to calculate cor-
relations among the variables. To assess links between MSFigure 3 Restriction fragments length polymorphism (RFLP)
distribution pattern of LEPR Gln223Arg polymorphism. Lane 1 =
ladder (50 bp), Lane 2 = Gln/Gln (421 bp), Lane 3 = Arg/Arg (294
and 127 bp), Lane 4 = Gln/Arg (421, 294 and 127 bp).
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regression was applied. A p-value < 0.05 was considered
statistically significant. Goodness-of-fit of the logistic re-
gression models was established by Hosmer-Lemeshow
test.
Results
Anthropometric and biochemical data of the MS and
control groups are shown in Table 1. Serum leptin levels
were significantly higher in the MS group than the con-
trol group (p < 0.01), while lower HDL-C levels were ob-
served in MS group as compared to the control group
(p < 0.01). Meanwhile, there were significant differences
between the MS and control groups in glucose, insulin,
TG, systolic BP, diastolic BP, BMI, waist/hip ratio, WC,
AC and TSF (p < 0.01). The BDNF difference between
the MS and control groups was not significant. Spear-
man’s Rank correlation test results are shown in Table 2.
Leptin level was positively correlated with age, insulin,
TG, systolic BP, diastolic BP, BMI, waist/hip ratio, WC,
AC and TSF, but negatively correlated with HDL-C level
(p < 0.05). Moreover, BDNF level correlated significantly
with age, AC and TSF, as shown in Table 2.
To evaluate the associations of single-nucleotide poly-
morphisms (SNPs), LEPR Gln223Arg, LEP G2548A and
BDNF Val66Met, with leptin level, BDNF level and
metabolic features we performed multivariate analysis.Table 1 Comparison of anthropometric, biochemical
variables and age between individuals with and
without MS
Variables Control (n = 162) MS (n = 160)
p-value
Median (range) Median (range)
Age (years) 46.0 (24.0-64.0) 48.0 (28.0-63.0) 0.241
Leptin (ng/mL) 6.2 (2.2-32.3) 11.4 (2.9-36.8) <0.001**
BDNF (ng/mL) 11.7 (2.8-29.2) 11.5 (2.7-27.8) 0.946
Glucose (mg/dL) 84.0 (66.0-113.0) 95.5 (70.0-134.0) <0.001**
Insulin (μU/mL) 11.7 (4.5-30.7) 15.8 (5.6-37.3) <0.001**
TG (mg/dL) 84.0 (58.0-270.0) 169.0 (63.0-302.0) <0.001**
HDL-C (mg/dL) 50.0 (28.0-77.0) 40.0 (27.0-71.0) <0.001**
Systolic BP (mmHg) 120.0 (95.0-160.0) 130.0 (100.0-170.0) <0.001**
Diastolic BP (mmHg) 74.0 (60.0-95.0) 80.0 (64.0-100.0) <0.001**
BMI (kg/m2) 22.8 (18.9-35.5) 26.5 (19.5-37.9) <0.001**
Waist/Hip ratio 0.82 (0.69-0.97) 0.88 (0.72-0.99) <0.001**
WC (cm) 77.0 (61.5-101.3) 91.0 (66.5-106.0) <0.001**
AC (cm) 27.5 (21.8-34.0) 30.2 (22.9-38.5) <0.001**
TSF (mm) 17.9 (6.5-37.5) 26.0 (8.5-40.9) <0.001**
Abbreviation: BDNF Brain-derived neurotrophic factor, TG triglyceride,
HDL-C high-density lipoprotein cholesterol.
BMI Body mass index, WC waist circumference, AC arm circumference,
TSF triceps skin-fold thickness.
Significant level;** = p < 0.01 by Mann-Whitney U / Wilcoxon Rank Sum W
test (2-tailed).Significant associations of LEPR Gln223Arg polymorphism
were found with leptin and glucose levels, after adjusting
for potential covariates including age, sex, weight and
smoking status; the results are shown in Table 3. There
were no significant associations of LEP G2548A and BDNF
Val66Met polymorphisms with leptin level, BDNF level and
metabolic features (p > 0.05); the results are shown in
Table 3. The genotypes of SNPs LEPR Gln223Arg, LEP
G2548A and BDNF Val66Met were in Hardy-Weinberg
equilibrium (HWE) (p > 0.05) and the values of chi-square
and degrees of freedom were shown in Table 4. Moreover,
the results in genotypic and allelic frequencies of LEPR
Gln233Arg, LEP G2548A, and BDNF Val66Met polymor-
phisms in MS and control subjects are also shown in
Table 4. There were significant differences in genotypic and
allelic frequencies of LEPR Gln233Arg polymorphism be-
tween MS and control groups (p < 0.05), but genotypic and
allelic distributions of LEP G2548A and BDNF Val66Met
polymorphisms between these two groups were not signifi-
cantly different (p > 0.05).
Association between LEPR Gln233Arg, LEP G2548A
and BDNF Val66Met polymorphisms and MS among
study subjects are shown in Table 5. Polymorphism of
LEPR Gln223Arg showed a significant link to MS (OR =
1.8, p < 0.05), and Gln/Arg with Arg/Arg genotype
frequencies in the MS and control groups were 62.5%
and 48.8%, respectively. In contrast, LEP G2548A and
BDNF Val66Met polymorphisms were not related to MS
(p > 0.05).Table 2 Correlation coefficients of leptin as well as BDNF









Systolic BP 0.358** -0.018
Diastolic BP 0.199** -0.015
BMI 0.383** 0.036




Abbreviation: BDNF Brain-derived neurotrophic factor, TG triglyceride,
HDL-C high-density lipoprotein cholesterol, BMI Body mass index, WC waist
circumference, AC arm circumference, TSF triceps skin-fold thickness.
Significant levels;* = p < 0.05 by Spearman’s rank correlation (2-tailed).
**= p < 0.01 by Spearman’s rank correlation (2-tailed).
Table 3 Adjusted odds ratio for LEPR Gln223Arg, LEP G2548A and BDNF Val66Met polymorphisms with leptin level,
BDNF level and metabolic features






OR (95% CI) OR (95% CI) OR (95% CI)
Systolic BP 0.989 (0.952-1.027) 0.568 1.030 (0.982-1.090) 0.318 1.022 (0.978-1.068) 0.331
Diastolic BP 1.019 (0.968-1.072) 0.474 1.000 (0.932-1.073) 0.999 1.017 (0.972-1.075) 0.447
WC 0.991 (0.972-1.046) 0.437 1.044 (0.966-1.129) 0.270 0.968 (0.899-1.043) 0.410
TG 0.999 (0.993-1.004) 0.635 1.002 (0.994-1.009) 0.636 0.998 (0.991-1.007) 0.378
HDL-C 1.000 (0.974-1.038) 0.994 0.992 (0.945-1.041) 0.745 1.002 (0.965-1.029) 0.722
Glucose 1.047 (1.004-1.092) 0.033* 1.021 (0.989-1.065) 0.340 0.989 (0.965-1.019) 0.354
Insulin 1.016 (0.997-1.056) 0.099 0.985 (0.944-1.027) 0.473 1.009 (0.972-1.050) 0.600
Leptin 1.192 (1.038-1.379) 0.009** 0.924 (0.816-1.039) 0.209 0.963 (0.873-1.050) 0.903
BDNF 0.997 (0.950-1.045) 0.737 0.986 (0.925-1.051) 0.576 0.980 (0.943-1.045) 0.909
Abbreviation: BDNF Brain-derived neurotrophic factor, TG triglyceride, HDL-C high-density lipoprotein cholesterol.
WC waist circumference, LEP leptin gene, LEPR leptin receptor gene, BDNF Brain-derived neurotrophic factor gene.
Significant levels;* = p < 0.05, **= p < 0.01.
Table 4 Genotypic and allelic distribution of LEPR Gln233Arg, LEP G2548A, and BDNF Val66Met polymorphisms in MS
and control subjects
MSn (%) HWE of MS p-valuea Control n (%) HWE of control p-value* Genotypic or allelic p-valueb
LEPR Gln233Arg
Genotype
Arg/Arg 20 (12.5) 0.399 17 (10.5) 0.295
0.044*Arg/Gln 80 (50.0) (df = 1) 62 (38.3) (df = 1)
Gln/Gln 60 (37.5) (χ2 = 0.71) 83 (51.2) (χ2 = 1.09)
Allele
Arg 120 (0.375) 96 (0.296)
0.034*
Gln 200 (0.625) 228 (0.704)
LEP G2548A
Genotype
A/A 58 (36.2) 0.638 55 (34.0) 0.483
0.439A/G 79 (49.4) (df = 1) 75 (46.3) (df = 1)
G/G 23 (14.4) (χ2 = 0.22) 32 (19.7) (χ2 = 0.49)
Allele
A 195 (0.609) 185 (0.571)
0.321
G 125 (0.391) 139 (0.429)
BDNF Val66Met
Genetype
Met/Met 32 (20.0) 0.479 30 (18.5) 0.544
0.327Met/Val 84 (52.5) (df = 1) 75 (46.3) (df = 1)
Val/Val 44 (27.5) (χ2 = 0.50) 57 (35.2) (χ2 = 0.37)
Allele
Met 148 (0.463) 135 (0.417)
0.241
Val 172 (0.537) 189 (0.583)
Abbreviation: HWE Hardy-Weinberg equilibrium, LEP leptin gene, LEPR leptin receptor gene, BDNF Brain-derived neurotrophic factor gene.
Significant level;* = p < 0.05.
aBased on the results of chi-square test.
bBased on the results of chi-square test for the comparison between MS and control groups.
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Table 6 Logistic regression analysis when MS was used as
a dependent variable, and age, sex, TSF, waist/hip ratio,
insulin, leptin, LEPR Gln223Arg, LEP G2548A and BDNF
Val66Met, were taken as independent variables
Variables β p-value OR (95% CI)
Leptin 0.46 0.007* 1.91 1.25-3.03
LEPR Gln223Arg 2.37 0.033* 9.07 1.22-37.14
Waist/hip ratio 5.58 <0.001* 22.04 2.42-91.36
TSF 0.17 0.029* 1.31 1.03-1.95
Sex -2.34 0.335 0.20 0.02-6.26
Age 0.03 0.625 0.97 0.89-1.14
Insulin 0.07 0.101 1.10 0.98-1.21
BDNF Val66Met 0.88 0.179 2.39 0.74-8.54
LEP G2548A 1.84 0.124 6.03 0.80-26.11
Abbreviation: LEP leptin gene, LEPR leptin receptor gene, BDNF
Brain-derived neurotrophic factor gene, TSF triceps skin-fold thickness.
Significant level; *= p < 0.05.
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tween MS and age, sex, TSF, waist/hip ratio, insulin,
leptin, LEP G2548A, LEPR Gln223Arg and BDNF Val66-
Met, are shown in Table 6. Of these variables, leptin,
LEPR Gln223Arg, TSF and waist/hip ratio were signifi-
cantly related to MS (p < 0.05). The Hosmer-Lemeshow
Goodness-of-Fit test (χ2 = 0.896, p > 0.05) was not sta-
tistically significant; the fit between the predictive model
and the data was acceptable.
Discussion
To the best of our knowledge, this is the first study to
examine the links of leptin level, BDNF level, and
polymorphisms of LEPR Gln223Arg, LEP G2548A and
BDNF Val66Met with MS among Thais. The key obser-
vations of this study were that leptin levels were signifi-
cantly higher in the MS group than in the control group,
and that the LEPR Gln223Arg polymorphism showed a
significant link to leptin concentrations and MS among
Thais. In contrast, LEP G2548A and BDNF Val66Met
polymorphisms were not related to MS.
MS is a cluster of risk factors predictive of future
cardiovascular diseases and type 2 diabetes mellitus [1].
Factors which appear to promote the development of
MS include genetics, obesity, physical inactivity and an
unhealthy diet. Mechanisms causing the onset of this
syndrome, however, are still not clearly understood.
Leptin is an adipocyte-derived signaling factor that has
an important role in metabolic control, such as in stimu-
lating glucose uptake, fatty acid oxidation, and reducing
food intake [2,22]. Moreover, circulating leptin levelsTable 5 Association between LEPR Gln233Arg, LEP
G2548A and BDNF Val66Met polymorphisms and MS
SNPs Genotype frequencies OR (95% CI) p-valuea
MS n (%) Control n (%)
LEPR Gln223Arg
Genotype
Arg/Arg + Arg/Gln 100 (62.5) 79 (48.8) 1.8 (1.2-2.7) 0.013*
Gln/Gln 60 (37.5) 83 (51.2)
LEP G2548A
Genotype
A/A + A/G 137 (85.6) 130 (80.2) 1.5 (0.8-2.6) 0.200
G/G 23 (14.4) 32 (19.8)
BDNF Val66Met
Genotype
Met/Met + Met/Val 116 (72.5) 105 (64.8) 1.4 (0.8-2.5) 0.230
Val/Val 44 (27.5) 57 (35.2)
Abbreviation: LEP leptin gene, LEPR leptin receptor gene, BDNF
Brain-derived neurotrophic factor gene.
Significant level;* = p < 0.05.
aBased on the results of chi-square test.are closely related to stored adipose tissues [3] and
metabolic function [22]. However, most previous studies
have focused on the relationship between leptin and
obesity, and each component of MS, instead of a cluster
of MS components. Therefore, the present study investi-
gated links between leptin and MS among Thais, espe-
cially. Our results were in accordance with previous
studies in Korean populations [23] and Lebanese volun-
teers [24], in that serum leptin was associated with MS.
Bremer et al. also showed increased amounts of sub-
cutaneous adipose tissue secretion and circulating leptin
concentrations in subjects with nascent MS [25]. In-
creased leptin concentration in MS may represent a
form of leptin resistance, as in obese subjects [26]; obes-
ity is one of the risk factors for MS. Therefore, alterna-
tion of leptin levels may be a part of the etiology of MS.
Leptin exerts a number of significant influences, by
binding and activating specific leptin receptors in the
hypothalamus and other organs including pancreatic β
cells, adipose tissue, and muscle. Previous studies re-
ported LEPR polymorphisms were associated with glu-
cose metabolism [27] and insulin resistance [5], possibly
leading to a predisposition towards greater MS risk.
LEPR Gln223Arg polymorphism has been associated
with impaired signaling capacity of the leptin receptor
[8]. LEPR Gln223Arg polymorphism has also been
linked with impaired glucose tolerance and conversion
to type 2 diabetes [27]. Our study was therefore inter-
ested in this position of the LEPR gene polymorphism.
Present data points to a relationship between LEPR
Gln223Arg polymorphism and increased leptin and glu-
cose levels in Thai subjects, similar to results in Dutch
adults [28] and Romanian subjects [29]. In contrast to
our results, however, LEPR Gln223Arg polymorphism
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Turkish children [11]. Moreover, few studies have deter-
mined a correlation between LEPR gene polymorphism
and MS. Our findings among Thais were in accordance
with results from a sample of elderly Brazilian subjects
[9], which showed links between LEPR Gln223Arg poly-
morphism and MS. On the other hand, the study in
Turkish children did not find any relation between LEPR
Gln223Arg polymorphism and MS [11]. Therefore, our
study demonstrated that LEPR Gln223Arg polymorph-
ism in Thai subjects was associated with increased MS
risk, which may be explained by increasing glucose and
leptin levels. Although the pathogenesis of MS and each
of its components is complex and not well understood,
our investigation proposes that LEPR Gln223Arg poly-
morphism associated with increased leptin levels may
represent a modified functional leptin receptor and may
take part in the development of MS. The previous stud-
ies also suggested that LEPR Gln223Arg polymorphism
has been associated with insulin resistance capacity and
an altered leptin-binding activity [30] and the leptin
can modulates insulin secretion and action via leptin
receptors in pancreatic β cells [31].
Although many researches indicate a role for genetic
susceptibility to the MS and our results supporting the
relationship between the LEPR Gln223Arg polymorph-
ism and increased MS risk among Thais, lifestyle factors
have also found to be affecting factors in the pathogen-
esis and progression of MS. Thailand has importantly
experienced economic transition and its structure has
gradually changed from the traditional agricultural sur-
roundings to an industrialized structure. The dietary
intake pattern in Thais has changed from traditional
high-carbohydrate diets, which rely heavily on rice and
vegetables, to diets high in fat and sugar; physical activ-
ity has progressively declined [32]. These transitions
have consequently resulted in increasing the prevalence
of MS in Thailand [33].Therefore, lifestyle interventions
including eating healthy diet and improving physical ac-
tivity should be regarded as important management for
reducing the development of MS among Thais, espe-
cially in SNP LEPR Gln223Arg subjects. With regard to
links between LEP G2548A gene polymorphism and lep-
tin levels, the previous study reported a common gene
polymorphism in the promoter LEP G2548A influencing
leptin expression and adipose tissue secretion of leptin
[7]. However, studies yielded inconsistent results; data
in Egyptian subjects [34] and Romanian subjects [29]
points to a relationship between LEP 2548GG variants
and serum leptin levels, meanwhile studies in Melanesian
and Micronesian Solomon Islanders [35] found no relation-
ship between LEP G2548A polymorphism and leptin levels,
consistent with our results among Thais. In investigating
the links between LEP G2548A polymorphism and MS,LEP G2548A polymorphism was shown to be significantly
associated with MS in Tunisian volunteers [10] and
Egyptian subjects [34], while no links were found in our
study. Investigations among Romanian subjects also found
no association of the LEP G2548A polymorphism with
common obesity-related variables and metabolic traits [29].
It is possible that inconsistencies among the results of the
LEP and LEPR gene polymorphisms in these studies are the
result of the different genetic backgrounds or environmen-
tal conditions of the populations studied.
BDNF is involved in regulating energy homoeostasis,
blood glucose levels, and eating behaviors, and it appears
to function downstream of the leptin-melanocortin
signaling pathway [13,36]. BDNF is expressed at high
levels in the ventromedial hypothalamus (VMH) where
its expression is regulated by nutritional state and by
melanocortin-4 receptor (MC4R) signaling [36]. More-
over, Komori et al. demonstrated that administration of
leptin causes an increase in expression of BDNF mRNA
and protein in the VMH [37]. The precise mechanism
that mediates BDNF expression by leptin remains to be
elucidated and there are two evidences that have been
proposed. The first possibility is that the LEP- LEPR
interaction directly triggers a signal transduction cascade
that induces BDNF in the VMH. The second option
involves the leptin-mediated production of the melano-
cortin precursor α-melanocyte stimulating hormone (α-
MSH) in the arcuate nucleus, which activates BDNF in
the VMH via MC4R [13]. However, the mechanistic im-
plication of the association between leptin, BDNF and
the LEPR gene in MS is unclear. Our results may imply
that Thai MS subjects have related to LEPR Gln223Arg
polymorphism and increased leptin levels representing a
form of leptin resistant. These defects may be involved
in the LEP-LEPR interaction in mechanisms induced
BDNF expression by leptin signaling. Although previous
studies have investigated a correlation between BDNF
levels and MS, these investigations have shown incon-
sistent results of BDNF levels in subjects with MS
[16,17,38,39]. In examining links between BDNF concen-
trations and BDNF Val66Met gene polymorphisms with
MS among Thais, the present study found neither BDNF
concentrations nor BDNF gene polymorphism relates to
MS. Our results were in line with studies in Spanish and
Taiwanese subjects, in that, BDNF concentrations did
not correlate with MS and any metabolic syndrome
component [16,38]. In contrast, other reports have
found BDNF levels to be linked with MS, and with sev-
eral features of MS [17,39]. However, data on BDNF
Val66Met gene polymorphism with MS is scarcely avail-
able. Indeed, ours is the first publication to determine
these associations among Thais. Previous studies found
that BDNF Val66Met gene polymorphism influenced
BDNF expression and/or activity [15], and was related to
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Caucasian subjects found no significant association
between Val66Met gene polymorphism and MS [41].
Similarly, our results confirm this polymorphism not to
be linked with MS or with features of MS. Therefore,
our findings suggest that BDNF concentrations and
BDNF Val66Met polymorphism are not involved in the
pathophysiology of MS among Thais. However, the rela-
tionship between BDNF levels and gene polymorphisms
with MS is still not clearly understood, and further stud-
ies should be undertaken investigating different ethnici-
ties, as well as other points of the BDNF gene.
There are a few limitations of our study. We did not
analyze the whole gene of LEP, LEPR and BDNF with
MS and further studies should be replicated our findings
in larger sample numbers.
In conclusion, the present study found leptin concen-
trations of MS subjects to be higher than the controls.
Although no correlations between MS with BDNF level
or BDNF Val66Met were observed, there was an associ-
ation between LEPR Gln223Arg polymorphism and lep-
tin level and MS. Therefore, genetic polymorphism in
the LEPR Gln223Arg appeared to affect the leptin con-
centration and the susceptibility to MS and these find-
ings might play a significant function in the etiology of
MS among the Thai population. Moreover, we believe
further studies on MS genetics will help to develop
preventive strategies and the role of other genetic and
environmental factors should be studied in the other
populations.
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